Congress Clarifies Orphan Drug Exclusivity & Generic Transparency
A sweeping federal spending package enacted this week includes two long-sought policy changes for FDA — clarifying the scope of orphan drug exclusivity and easing long-standing regulatory hurdles for generic drug developers. The provisions are included in the Consolidated Appropriations Act of 2026, and reflect years of lobbying by the agency to address court decisions and administrative constraints that agency officials say have impeded competition in the pharmaceutical market. In addition to renewing the Rare Pediatric Disease Priority Review Voucher program (see earlier story), the legislation amends the Orphan Drug Act to narrow the scope of market exclusivity and revises rules governing how FDA communicates formulation requirements to generic drug applicants.
One of the most consequential changes addresses the fallout from a 2021 decision by the U.S. Court of Appeals for the Eleventh Circuit in Catalyst Pharmaceuticals Inc. v. FDA, according to an FDA Law Blog post. In that case, the court ruled that orphan drug exclusivity applies to the entire designated rare disease or condition, rather than only to the specific indication approved by FDA. The decision limited the agency’s longstanding interpretation of the Orphan Drug Act, under which exclusivity attaches only to the approved use or indication. Although it said at the time it would apply the Catalyst ruling narrowly, the agency faced continued litigation challenging that position.
Congress has now stepped in and the new law replaces the phrase “same disease or condition” with “same approved use or indication within such rare disease or condition,” explicitly restoring FDA’s prior interpretation, according to the post. Under the revised statute, orphan drug exclusivity blocks approval of the same drug only for the same indication, not across the entire disease. The amendment applies retroactively, regardless of when a drug received orphan designation or approval. As a result, FDA will need to review existing orphan drug exclusivities to determine how broadly they apply under the new standard.
The appropriations law also makes a significant change to how FDA communicates with generic drug developers, particularly products required to be qualitatively and quantitatively the same as their reference listed drug. Under existing regulations, some generic drugs must match not only the active ingredient but also the type and amount of inactive ingredients — commonly referred to as being “Q1/Q2 the same,” according to the FDA Law Blog.
Until now, FDA could tell applicants that a proposed formulation was not Q1/Q2 equivalent but could not disclose what changes were needed or how far off the formulation was. As a result, applicants often submitted multiple rounds of controlled correspondence, effectively guessing until they matched the reference product. The new law amends section 505(j)(3) of the Federal Food, Drug, and Cosmetic Act to allow FDA to disclose whether a proposed generic differs qualitatively or quantitatively from the listed drug and to explain why. The change is intended to increase transparency and reduce unnecessary delays in generic drug development.